Blueprint Medicines, headquartered in Cambridge, Massachusetts, develops precision therapies for cancer and blood disorders, employing 645 fulltime staff. It has approved medicines like AYVAKIT and GAVRETO, with ongoing research in various cancers.
BPMC has been in the news recently: Sanofi SA has agreed to acquire Blueprint Medicines Corporation for an undisclosed amount. In recent months, eight analysts have provided varying ratings on Blueprint Medicines, indicating mixed opinions on the company's performance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
